Improving the lives of millions of people with non-invasive disease detection through a scan of the eye
Business overview
| Location | London, United Kingdom |
|---|---|
| Social media | |
| Website | www.occuity.com |
| Sectors | Healthcare Mixed Digital/Non-Digital Mixed B2B/B2C |
| Company number | 12192959 |
| Incorporation date | 6 Sep 2019 |
Investment summary
Business highlights
- Enabling screening of glaucoma, myopia & diabetes
- Optical MedTech: 15 patents & £4m grant funding
- First product selling globally via 19 distributors
- Proven platform & strategic pipeline of products
Key features
Pitch
About the Campaign
Occuity is developing handheld, non-contact devices that use the eye as a window to the health of the body. Our patented optical technology is already addressing glaucoma & myopia, with future products targeting disease screening & ultimately a non-invasive glucose meter for diabetes monitoring.
Market Opportunity
•Optical platform provides competitive advantage in multiple MedTech markets:
•Ophthalmic Devices $5bn; Glucose Monitoring $17bn; Disease Screening $20bn
•Tackling pandemic diseases which affect millions of people globally
•Future Opportunity: Data collection, AI analysis & data monetisation
Traction & Key Accomplishments
• £9m+ raised to date
• Team & Technology: Recognised with multiple engineering & innovation awards
• Experienced Leadership: previous successful exits
• Patent Thicket: 14 Granted, 1 Pending, 6 draft
• PM1 Pachymeter: Achieved CE mark in 2024. Now generating revenue via 19 global distributors
• AX1 Axiometer: Launching in 2026 – ongoing discussions with several global corporates in myopia market
• Oculomics Projects: £4m grant funding – Enabled working prototypes validated with clinical data
Use of Funds
Funds used to:
• Accelerate AX1 commercial launch
• Expand PM1 production & distribution
• Advance SD1 & Indigo R&D programmes & Oculomics platform development in conjunction with existing & new grant funding
• Strengthen sales, regulatory & manufacturing capability
• Support global scaling
Key Information
Key information investment sheet
Key Investment Information Sheet is available by downloading the following documents:
- Key Investment Information Sheet [Danish]
- Key Investment Information Sheet [German]
- Key Investment Information Sheet [English]
- Key Investment Information Sheet [Spanish]
- Key Investment Information Sheet [French]
- Key Investment Information Sheet [Italian]
- Key Investment Information Sheet [Dutch]
- Key Investment Information Sheet [Portuguese]
- Key Investment Information Sheet [Swedish]
Material debt
The Company has the following outstanding loans:
£24,476.00 founder loan with no interest rate.
£20,388.00 founder loan with no interest rate.
The funds raised as part of this round will not be used to repay these loans, which are currently being repaid and included in monthly cash burn.
Outstanding creditors
The company currently has £277k of trade and other creditors outstanding.
Cash runway
The company is planning to raise £2m or more through a variety of sources. As one of the sources in this round, the company aims to raise a minimum of £1.1m via its Republic Europe campaign, representing at least 6 months of runway. In addition to this, and any overfunding from Republic Europe, the company anticipates further capital will be raised from additional investors.
Share classes
The company currently has 4 classes of shares: Ordinary Shares, A Ordinary Shares, B Ordinary Shares and Preferred Ordinary Shares. Prior to the current investment round, no A Ordinary have yet been issued.
The majority of offline investors in the round, including Republic Europe investors, will be receiving Ordinary Shares. £127,000 from offline investors have chosen Preferred Ordinary Shares, although these do not have EIS eligibility.
The rights attached to the share classes are as follows:
Preferred Ordinary Shares:
• Voting rights
• On a liquidation or exit:
- If the proceeds per share are £48 or less, Preferred Ordinary Shareholders will receive a 1 x participating preference.
- If the proceeds per share are between £48 and £72, Preferred Ordinary Shareholders will receive a ratcheted participating preference of 1x or less.
- If the proceeds per share are £72 or more, Preferred Ordinary Shareholders have no preference and will participate pro rata with the Ordinary and A Ordinary Shareholders.
B Ordinary Shares (Growth Shares):
• No voting rights
• On a liquidation or exit: an amount per share equal to the proceeds per share less £8.8125 i.e if on an exit, proceeds per share were £70, B Ordinary Shareholders would receive £61.1875 per share (after the Preferred Ordinary Shareholders had received 0.833 x their initial investment amount).
Ordinary Shares:
• Voting rights
• No preference on liquidation or exit, right to participate pro rata after the Preferred Ordinary and B Ordinary preferences.
A Ordinary Shares (Staff Option Scheme):
• No voting rights
• No preference on liquidation or exit, right to participate pro rata after the Preferred Ordinary and B Ordinary preferences.
Convertible Loan Notes
As part of this funding round, two existing Convertible Loan Notes (CLNs) are converting from debt into company shares. The shares being issued for these converting loans have already been included in the pre-money valuation shown for this investment offer. The number of shares these loans will receive were calculated using a "maximum case scenario." This means we have assumed the highest likely number of shares to be issued, ensuring the valuation you see already accounts for this and there’s no hidden future dilution from these CLNs.
Open an account to get access to the team members of Occuity
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Only shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy shares
